跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
CONTRAVE - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
CONTRAVE
Authorized
STANDARD
CONTRAVE
bausch health, canada inc.
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
fb1926a8e61adad1
Company
bausch health, canada inc.
Type
Standard
Approval Details
Approval Id
fb1926a8e61adad1
Drug Approval Canada Name
CONTRAVE
Product Name
CONTRAVE
Status
Marketed
Status Date
2020-06-02
Original Market Date
2018-03-16
Din
02472945
Drug Class
Human
Dosage Form
Tablet (Extended-Release)
Route Of Administration
Oral
Schedule
Prescription
Ahfs
28:20.08.92
Atc Original
A08AA62 BUPROPION AND NALTREXONE
Atc Name
a 08 aa 62
Aig Number
0259950001
Company Name
bausch health, canada inc.
Company Address
2150 Boul. St-Elzear Ouest, Laval, Quebec, Canada, H7L 4A8
Active Ingredients
BUPROPION HYDROCHLORIDE
90 MG
NALTREXONE HYDROCHLORIDE
8 MG
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
fb1926a8e61adad1
Type
Standard
Back to Health Canada Approvals